Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 12Phase 1/2 5Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 4Gastrointestinal 2Thoracic 1Sarcoma 1Genitourinary 1

Conditions

Gliosarcoma 1

Interventions

Doxorubicin 7Radiotherapy 4Radiation 3Magnetic Resonance Spectroscopy 3Ifosfamide 3regorafenib 2Temozolomide 2Surgical Procedures, Operative 2Methotrexate 2Imatinib Mesylate 2Etoposide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2veliparib 1selinexor 1pirarubicin 1pazopanib 1niraparib 1merphos 1liposomal doxorubicin 1fludarabine phosphate 1dostarlimab 1capmatinib 1cabozantinib 1brigimadlin 1apatinib 1anlotinib 1Zoledronic Acid 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Ipilimumab × Sarcoma × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡